Tumour Registry Lung Cancer (TLK)
This trial has been completed.
|Start date||January 2010|
|End date||July 2016|
|Trial size||2500 participants|
|Trial identifier||NCT01192919, IOM TLK|
Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.
Patients with lung cancer requiring therapy
Documentation of actually used therapy forms in bronchial carcinoma requiring treatment
time frame: 3 years per patient
Male or female participants at least 18 years old.
- histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
- written informed consent
- start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent
- patients not receiving any systemic therapy
|Official title||Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.|
|Principal investigator||Hans-Werner Tessen, MD|
|Description||The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.|
Call for more information